Predicting therapeutic response to fingolimod treatment in multiple sclerosis patients

AIMS: Fingolimod, an orally active immunomodulatory drug for relapsing‐remitting multiple sclerosis (RRMS), sequesters T cells in lymph nodes through functional antagonism of the sphingosine‐1‐phosphate receptor, reducing the number of potential autoreactive cells that migrate to the central nervous...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:CNS Neurosci Ther
Glavni autori: Quirant‐Sánchez, Bibiana, Hervás‐García, José V., Teniente‐Serra, Aina, Brieva, Luis, Moral‐Torres, Ester, Cano, Antonio, Munteis, Elvira, Mansilla, María J., Presas‐Rodriguez, Silvia, Navarro‐Barriuso, Juan, Ramo‐Tello, Cristina, Martínez‐Cáceres, Eva M.
Format: Artigo
Jezik:Inglês
Izdano: John Wiley and Sons Inc. 2018
Teme:
Original Articles
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6489963/
https://ncbi.nlm.nih.gov/pubmed/29656444
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cns.12851
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items